Atlas Venture, a Cambridge, Mass.-based early stage venture capital and venture creation firm investing in biotech innovation, closed its second Opportunity Fund, at $300m.
Led by David Grayzel, Kevin Bitterman, Bruce Booth, Jean-François Formela, Michael Gladstone, and Jason Rhodes, Atlas Venture Opportunity Fund II (AVOF II), will enable the firm to continue its model of supporting its portfolio companies as they raise subsequent financings and advance therapeutic programs.
Atlas Venture is a biotech venture capital and venture creation firm. Its seed-led venture creation strategy rigorously selects and focuses investment on the most compelling opportunities to build scalable businesses and realize value.
The firm works alongside its group of experienced entrepreneurs-in-residence and venture partners to create new biotech companies based on innovative insights from the global scientific community and the team’s entrepreneurial networks. The firm incubates many of its portfolio companies in its Kendall Square space.
FinSMEs
01/10/2021